Weekly Horoscope (July 14 – July 20): Predictions for Goat Chinese Zodiac
Do not ignore it. Even small progress is still progress. This week reminds you that big strength comes from small, steady steps. Feel proud. You are moving more than you know.
Weekly Career
Horoscope
for
Goat Chinese Zodiac
At workplace, a task you once found hard will now feel easier. This is the result of your patience and effort. A small compliment or result may come—notice it. Your silent work is speaking now. Keep doing your duty without rush. You are building something strong.
This is not the time to change direction. Continue with same effort and let results grow quietly but surely.
Weekly Love Horoscope for Goat
Chinese Zodiac
In love, you may feel closer to your partner just through one small moment—like a smile, a gesture or a kind word. These are signs of growing bond. If you are single, you may realise that your heart is healing from a past pain. Celebrate even this small healing. Love does not always shout—it often grows in silence. Feel the beauty of the gentle progress.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Dukung Orang Terkasih Menghadapi Limfoma: Mulai Di Sini
Limfoma
Klik Di Sini
Undo
Weekly Money Horoscope for Goat Chinese Zodiac
This week, you may feel financially more balanced than before. Maybe it's a small saving or a bill paid on time. These are achievements. Don't wait for big success to feel satisfied. Small wins in money build your future. Continue being wise with expenses. Appreciate your growing stability. You may receive small help or gift—accept it with gratitude. Peace comes through small and simple steps.
Weekly Education Horoscope for Goat Chinese Zodiac
In studies, a topic that once felt confusing will now make sense.
This is your progress. Trust your method and don't change it suddenly. If someone praises your effort, accept it. One good mark or clear understanding is proof of your steady growth. Do not look down on small achievements. Learning builds slowly, and you are on the right track. Keep faith in your quiet path.
Weekly Health Horoscope for Goat Chinese Zodiac
You may notice your body responding better to routine now. Even if it's just better sleep or less stress, it means your efforts are working. Continue with your gentle lifestyle. Avoid sudden changes. Support your digestion and skin health with warm food and rest. A small health improvement is still victory. Let this motivate you to stay on track. Slow health progress is strong progress.
Discover everything about
astrology
at the
Times of India
, including
daily horoscopes
for
Aries
,
Taurus
,
Gemini
,
Cancer
,
Leo
,
Virgo
,
Libra
,
Scorpio
,
Sagittarius
,
Capricorn
,
Aquarius
, and
Pisces
.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
40 minutes ago
- Time of India
Bandhan Mutual Fund completes 25-year milestone in Indian MF industry
Bandhan Mutual Fund completes 25 years in the Indian mutual fund industry, marking a legacy built on trust, innovation and unwavering commitment to helping savers become investors. To mark this milestone with its investors and partners, Bandhan AMC presents 'Raju Bhaiya Ki Kahani,' a nostalgic, music-led film that reflects the journey familiar to many: from saving to investing with confidence, according to a press release by the fund house. Also Read | Nearly 112 lakh SIPs closed in 2025: Should you worry about the negative net SIP trend? Best MF to invest Looking for the best mutual funds to invest? Here are our recommendations. View Details » by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Victoria Principal Is Almost 75, See Her Now The Latest Article Undo Told through a heartfelt jingle and evocative animation, it celebrates the progress of everyday investors over the years, the release added. 'As we mark 25 years of our journey, we are proud of the role we have played in helping millions of savers become investors. From our origins as ANZ Grindlays Mutual Fund to Standard Chartered Mutual Fund to IDFC AMC to now becoming Bandhan AMC, every milestone has been a testament to our commitment to financial inclusion, innovation and investor-centricity,' said Vishal Kapoor , CEO, Bandhan AMC. Live Events 'While we celebrate this legacy, we remain focused on the road ahead- dedicated to empowering investors, expanding access to prudent financial solutions and redefining what is possible. We are deeply grateful to our investors, partners, employees and all stakeholders for their enduring trust and support throughout the years,' Kapoor added. Over the last 25 years, the fund house has been a pioneer in innovation, being the first to introduce products such as Short-Term Fund, Government Securities Fund, Dynamic Bond Fund, Medium Term Fund and roll-down structures in debt schemes, the release said. It has also embraced next-generation strategies like Artificial Intelligence led PMS products and Machine Learning based investment frameworks through offerings like NEO Equity PMS. Beyond product innovation, the company has played a vital role in investor education, launching well-received campaigns like One Idiot, Return of One Idiot, Dattey Raho, and Be Smart - Stay Invested, which have helped spread financial awareness across the country, the press release mentioned. Also Read | Mutual funds slashes cash allocation by Rs 13,000 crore in June; PPFAS and Quant MF join trend In 2025, Bandhan AMC continues to expand its reach with the launch of its 100th branch, new operations at GIFT City with three India-focused funds and Vedartha, a dedicated platform for wealth creation for both onshore and offshore investors. As Bandhan AMC steps into the future, the vision remains clear, to be a trusted partner in every Indian's financial journey, and to continue helping savers become investors.
Time of India
41 minutes ago
- Time of India
Pakistan cricket in turmoil! Audit exposes crores in corruption and overpayments
NEW DELHI: The Auditor General of Pakistan has flagged major financial irregularities amounting to millions of rupees within the Pakistan Cricket Board (PCB), including unauthorised appointments and excess payments to match officials. The audit report points to instances of corruption during 2023, when the board was under the leadership of Mohsin Naqvi and Zaka Ashraf. Among the key findings is the misappropriation of 63.39 million Pakistani rupees paid to police for providing meals during international match security duties. The report also highlights the unauthorized hiring of three under-16 coaches at the Karachi High Performance Centre, which resulted in salary payouts of 5.4 million rupees. Go Beyond The Boundary with our YouTube channel. SUBSCRIBE NOW! Further, match officials were overpaid by 3.9 million rupees, raising concerns around potential match-fixing. The report also questions the hiring of a Media Director with a hefty monthly salary of 900,000 rupees. Additionally, the audit notes that ticketing contracts were awarded without following proper competitive bidding procedures. These revelations have further strained the PCB's already fragile administrative reputation. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it legal? How to get Internet without paying a subscription? Techno Mag Learn More Undo PCB Chairman Mohsin Naqvi—who concurrently serves as Pakistan's Interior Minister—is now under heightened scrutiny. However, his ministerial position grants him certain legal protections. Washington Sundar press conference: On Gautam Gambhir's support, last over drama, winning at Lord's The board has already come under fire following Pakistan's early exit from the Champions Trophy, which they hosted. Fans and officials have also criticised the frequent changes in coaching staff and team leadership over the past two years. These audit findings add to the growing list of controversies surrounding the PCB and offer detailed evidence of financial mismanagement within the country's cricket administration. For real-time updates, scores, and highlights, follow our live coverage of the India vs England Test match here. Catch Rani Rampal's inspiring story on Game On, Episode 4. Watch Here!
Time of India
an hour ago
- Time of India
AstraZeneca drug lowers high blood pressure in late-stage study
AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of patients with treatment-resistant hypertension. The news sent shares of the Anglo-Swedish drugmaker up by almost 2%. The company said it expects peak annual sales for the drug to exceed $5 billion, driven by its use as a standalone therapy and in combination with Farxiga , its blockbuster treatment - one that generates $1 billion or more in annual sales - for type 2 diabetes, heart failure and chronic kidney disease . by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 Most Beautiful Female Athletes in the World Click Here Undo Baxdrostat met the main and secondary goals of the study, showing a statistically significant and clinically meaningful reduction in systolic blood pressure at 12 weeks when added to standard treatment at two doses, and compared with placebo, AstraZeneca said. It acquired baxdrostat through its 2023 purchase of CinCor Pharma as part of efforts to expand its pipeline in heart and kidney disease. Live Events The drug targets aldosterone, a hormone that raises blood pressure, offering a new approach distinct from older treatments like ACE inhibitors that do not address hormonal drivers, AstraZeneca says. High blood pressure affects more than 1 billion people worldwide, according to the World Health Organization. AstraZeneca is testing baxdrostat in four indications, including chronic kidney disease and prevention of heart failure, in a clinical programme involving more than 20,000 patients. Shares in London's biggest listed company by market value were up 1.9% at 0834 GMT and among the top gainers on the FTSE 100 index in early trading. Mineralys Therapeutics is developing a similar drug, lorundrostat, and expects to submit data to the U.S. Food and Drug Administration by the end of the year. AstraZeneca said it will present full trial results at a medical conference in August but did not say when it will seek U.S. approval. Its shares are flat this year to date though they have outperformed Europe's benchmark healthcare index by about 5.5%, Barclays analysts said in a note on Monday.
